Stocknear Logo Stocknear
/
Popular
Login

HUTCHMED (China) Limited

15.10
0.11 (0.73%)
At close: Mar 24, 2025, 3:59 PM
15.09
-0.07%
After-hours: Mar 24, 2025, 04:05 PM EDT
0.73%
Bid 15.02
Market Cap 2.8B
Revenue (ttm) 123.8M
Net Income (ttm) -8.51M
EPS (ttm) 0.2
PE Ratio (ttm) 75.5
Forward PE 90.27
Analyst Hold
Ask 15.18
Volume 52,396
Avg. Volume (20D) 86,706.3
Open 15.06
Previous Close 14.99
Day's Range 15.01 - 15.22
52-Week Range 12.84 - 21.92
Beta 0.75

About HCM

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for ...

[Show more]
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
IPO Date Mar 16, 2016
Employees 1,811
Stock Exchange NASDAQ
Ticker Symbol HCM
Website https://www.hutch-med.com
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for HCM stock is "Hold." The 12-month stock price forecast is $19, which is an increase of 25.83% from the latest price.

Stock Forecasts

Why Price Moved

Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
6 days ago
+8.23%
HUTCHMED shares are trading higher. The company re... Unlock content with Pro Subscription
2 months ago
+4.65%
HUTCHMED shares are trading higher after the company announced the divestment of its 45% interest in Shanghai Hutchison Pharmaceuticals.
news image

3 days ago · businesswire.com

AI Becoming Essential to HCM, ISG Says

STAMFORD, Conn.--(BUSINESS WIRE)---- $III #AI--AI is becoming central to HCM and employee engagement, with two-thirds of enterprises expected to need AI-enabled capabilities by 2027, ISG says.

5 days ago · youtube.com

US pharma restrictions won't affect Hutchmed operations, says CEO

Weiguo Su, CEO of Chinese pharma company HUTCHMED, talks about  the company's latest earnings report, and why it's positioned to be 'sustainably profitable' from this point despite some external chall...

news image

6 days ago · seekingalpha.com

HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript

HUTCHMED (China) Limited (NASDAQ:HCM ) Q4 2024 Earnings Conference Call March 19, 2025 8:00 AM ET Company Participants David Ng - Head:IR Wei-Guo Su - CEO & Chief Scientific Officer Johnny Cheng - CFO...

news image

6 days ago · benzinga.com

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

On Wednesday, Hutchmed (China) Limited (NASDAQ: ​HCM) reported 2024 earnings of 22 cents per ADS or 4 cents per share, down 59 cents or 12 cents a year ago. Sales fell 25% year over year to $630.20 mi...

news image

1 month ago · zacks.com

HUTCHMED (HCM) Upgraded to Buy: Here's Why

HUTCHMED (HCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

news image

1 month ago · zacks.com

Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 72.8% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positi...

news image

2 months ago · benzinga.com

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

On Wednesday, Hutchmed (China) Limited HCM entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million (RMB 4.478 ...

news image

2 months ago · reuters.com

Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales

Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship conglomerate look to ramp up capital and pivo...

news image

3 months ago · seekingalpha.com

Paycor HCM: Positive On The Mid-Term Growth Outlook (Rating Upgrade)

I am upgrading PYCR to a buy rating due to optimistic mid-term guidance and strong earnings growth potential. PYCR's new guidance indicates sustainable mid-teens recurring revenue growth and >800 bps ...

Create Price Alert on HCM

Your price alert will notify you when the stock price is above 15.1.

Add to Watchlist